<DOC>
	<DOCNO>NCT02431143</DOCNO>
	<brief_summary>This multicenter , non-comparative , open-label clinical trial ass Pharmacokinetics ( PK ) safety miltefosine use allometric dose algorithm treatment child primary Visceral Leishmaniasis ( VL ) eastern Africa . Efficacy Pharmacodynamics ( PD ) assess secondary outcome . The propose study aim ass whether drug exposure child increase equivalent adult drug exposure use miltefosine allometric dose give BID 28 day paediatric VL patient age 4-12y whether dose tolerable . The present study also expect provide basis minimum time reach sufficient drug exposure miltefosine activity guide optimal treatment duration use combination therapy visceral leishmaniasis . The PK data assess trial use compartmental population PK approach .</brief_summary>
	<brief_title>Pharmacokinetics/Safety Miltefosine Allometric Dose Treatment Visceral Leishmaniasis Children Eastern Africa</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Patients clinical sign symptom VL confirmatory parasitological microscopic diagnosis Patients age &gt; 4 &lt; 12 year able comply study protocol . Patients write informed consent sign parent ( ) legal guardian Weight &lt; 30 kg Patients relapse case Patients receive antileishmanial drug last 6 month Patients severe malnutrition ( child age &lt; 5 year , weightforheight WHO reference curve gender , z score &lt; 3 ; child 512 year , BMIforage WHO reference curve gender , z score &lt; 3 ) Patients positive HIV diagnosis Patients previous history hypersensitivity reaction miltefosine Patients suffer concomitant severe infection Tuberculosis ( TB ) serious underlie disease ( cardiac , renal , hepatic ) would preclude evaluation patient 's response study medication Patients suffer condition associate splenomegaly schistosomiasis Pregnant lactate woman female patient childbearing age ( reach menarche ) Patients haemoglobin &lt; 5g/dl Patients White Blood Cells ( WBC ) &lt; 1 x 10³/mm³ Patients platelet &lt; 40,000/mm³ Patients abnormal liver function ( ALT AST ) test three time normal range . Patients bilirubin 1.5 time upper normal range Patients serum creatinine upper limit normal ( ULN ) age gender . Patients clinical sign severe VL disease jaundice bleed Patients comply plan schedule visit procedure study protocol</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>